Drug Trial Radar · NCT04051710
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
Last checked: Nov 19, 2026Latest source record: Nov 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,550
Actual
Start
Mar 12, 2019
Primary completion
Aug 29, 2019
Study completion Dec 20, 2019
Sponsor
- Lead sponsor
- Aurobindo Pharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the therapeutic equivalence of Beclomethasone Dipropionate MDI (Inhalation Aerosol) 0.04 mg/ INH with the marketed QVAR® 40 mcg (Beclomethasone dipropionate hydrofluoroalkane (HFA)) and to demonstrate superiority of both active treatments over placebo.
Conditions
- Bronchial Asthma
Interventions
Test ProductDrug
Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Reference ProductDrug
Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
PlaceboDrug
Placebo Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in FEV1 From Pre Dose to End of TreatmentTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Maharashtra Medical Foundation Joshi Hospital
Pune, Maharashtra, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.